CIBC Asset Management
DNLI icon

CIBC Asset Management’s Denali Therapeutics DNLI Stock Holding History

CIBC Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,069
Closed -$226K – 1538
2021
Q4 		$226K Buy
5,069
+186
+4% +$8.81K ﹤0.01% 1298
2021
Q3 		$246K Buy
4,883
+445
+10% +$25.1K ﹤0.01% 1168
2021
Q2 		$348K Hold
4,438
– – ﹤0.01% 923
2021
Q1 		$253K Buy
4,438
+827
+23% +$55.4K ﹤0.01% 1064
2020
Q4 		$302K Buy
+3,611
New +$218K ﹤0.01% 899

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

CIBC Asset Management's DNLI Position: Q1 2022 in Review

CIBC Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 5,069 shares — an estimated $226K sold.

CIBC Asset Management first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $348K in Q2 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • CIBC Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CIBC Asset Management sold 5,069 Denali Therapeutics shares in Q1 2022, an estimated $226K.
  • CIBC Asset Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
  • CIBC Asset Management's Denali Therapeutics position peaked at $348K in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on CIBC Asset Management's 13F filing for Q1 2022, filed 6 May 2022.